Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

MLA

Richardson, Paul G., et al. “Multi-Institutional Use of Defibrotide in 88 Patients after Stem Cell Transplantation with Severe Veno-Occlusive Disease and Multisystem Organ Failure: Response without Significant Toxicity in a High-Risk Population and Factors Predictive of Outcome.” Blood, vol. 100, no. 13, Dec. 2002, pp. 4337–43. EBSCOhost, https://doi.org/10.1182/blood-2002-04-1216.

APA

Richardson, P. G., Murakami, C., Jin, Z., Warren, D., Momtaz, P., Hoppensteadt, D., Elias, A. D., Antin, J. H., Soiffer, R., Spitzer, T., Avigan, D., Bearman, S. I., Martin, P. L., Kurtzberg, J., Vredenburgh, J., Chen, A. R., Arai, S., Vogelsang, G., McDonald, G. B., & Guinan, E. C. (2002). Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood, 100(13), 4337–4343. https://doi.org/10.1182/blood-2002-04-1216

Chicago

Richardson, Paul G, Carol Murakami, Zhezhen Jin, Diane Warren, Parisa Momtaz, Deborah Hoppensteadt, Anthony D Elias, et al. 2002. “Multi-Institutional Use of Defibrotide in 88 Patients after Stem Cell Transplantation with Severe Veno-Occlusive Disease and Multisystem Organ Failure: Response without Significant Toxicity in a High-Risk Population and Factors Predictive of Outcome.” Blood 100 (13): 4337–43. doi:10.1182/blood-2002-04-1216.